- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: Paliperidone palmitate.
Displaying page 1 of 1.
EudraCT Number: 2011-004889-15 | Sponsor Protocol Number: R092670PSY3011 | Start Date*: 2012-04-23 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects with Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) BE (Completed) DE (Completed) PT (Completed) AT (Completed) SE (Completed) DK (Prematurely Ended) SK (Completed) FI (Completed) GR (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001845-40 | Sponsor Protocol Number: R092670-PSY-3005 | Start Date*: 2005-08-24 |
Sponsor Name:Janssen-Cilag International N.V. | ||
Full Title: A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Subjects With Schizophrenia | ||
Medical condition: Schizophrenia according to DSM-IV-TM [disorganized type (295.10), catatonic type (295.20), paranoid type (295.30), residual type (295.60) or undifferentiated type (295.90)] | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) SK (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002694-22 | Sponsor Protocol Number: R092670PSY3002 | Start Date*: 2005-02-07 |
Sponsor Name:Janssen-Cilag International N.V | ||
Full Title: A Randomized, Double-Blind, Parallel Group Non-inferiority Study of Flexibly Dosed Paliperidone Palmitate(25, 50, 75, 100 mg eq) Administered Every 4 weeks and Flexibly Dosed Risperdal Consta (25, ... | ||
Medical condition: schizophrenia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) AT (Completed) SE (Completed) CZ (Completed) DK (Completed) EE (Completed) ES (Completed) LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004835-10 | Sponsor Protocol Number: R092670SCH3015 | Start Date*: 2016-03-23 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Pa... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) DE (Completed) ES (Completed) DK (Completed) GR (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004676-11 | Sponsor Protocol Number: R092670-PSY-3012 | Start Date*: 2012-08-30 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects with Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-018022-30 | Sponsor Protocol Number: R092670SCH3010 | Start Date*: 2010-11-05 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A 6-month, open label, prospective, multicenter, international, exploratory study of a transition to flexibly dosed paliperidone palmitate in patients with schizophrenia previously unsuccessfully ... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) HU (Completed) DE (Completed) NL (Completed) BE (Completed) ES (Completed) GB (Completed) SE (Completed) DK (Completed) IT (Completed) LV (Completed) AT (Completed) EE (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001941-28 | Sponsor Protocol Number: R092670PSY3015 | Start Date*: 2018-02-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6 Month Formulation. | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) CZ (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002247-16 | Sponsor Protocol Number: R092670SCH3005 | Start Date*: 2010-03-10 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit... | |||||||||||||
Medical condition: Recently diagnosed (1-5 years since diagnosis) schizophrenia. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) HU (Completed) ES (Completed) LT (Completed) BE (Completed) FR (Completed) EE (Completed) IT (Completed) BG (Completed) AT (Completed) GB (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006434-17 | Sponsor Protocol Number: R092670PSY3007 | Start Date*: 2007-05-03 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palm... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017271-17 | Sponsor Protocol Number: R092670-SCA-3004 | Start Date*: 2010-10-29 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder | |||||||||||||
Medical condition: Schizoaffective Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003560-62 | Sponsor Protocol Number: R092670PSY3006 | Start Date*: 2007-03-28 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects with Schi... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) EE (Completed) LT (Completed) DE (Completed) AT (Completed) FR (Completed) CZ (Completed) ES (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002785-12 | Sponsor Protocol Number: 14724A | Start Date*: 2013-03-20 | |||||||||||
Sponsor Name:H. Lundbeck A/S | |||||||||||||
Full Title: A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) IT (Completed) DE (Completed) ES (Completed) CZ (Completed) EE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007800-27 | Sponsor Protocol Number: R092670-SCH-3004 | Start Date*: 2009-10-15 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Prospective, Randomized, Active-controlled, Rater-blinded Study of the Prevention of Relapse Comparing Paliperidone Palmitate with Oral Risperidone in Adults with Recently-Diagnosed Schizophrenia... | |||||||||||||
Medical condition: Recently-Diagnosed Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004532-30 | Sponsor Protocol Number: R092670PSY3016 | Start Date*: 2019-08-09 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Single-arm, Open-label Extension to a Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002765-30 | Sponsor Protocol Number: ABR49490 | Start Date*: 2015-06-12 | |||||||||||
Sponsor Name:EGRIS | |||||||||||||
Full Title: European Long-acting Antipsychotics in Schizofrenia Trial EULAST | |||||||||||||
Medical condition: Schizophrenia ICD-10 code F20 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) AT (Completed) IT (Completed) NO (Completed) BE (Completed) ES (Completed) DK (Completed) HU (Completed) RO (Suspended by CA) CZ (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003435-38 | Sponsor Protocol Number: ACP-103-035 | Start Date*: 2017-04-28 | |||||||||||
Sponsor Name:ACADIA Pharmaceuticals Inc. | |||||||||||||
Full Title: A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) ES (Ongoing) BG (Prematurely Ended) CZ (Completed) DE (Prematurely Ended) LT (Completed) PL (Prematurely Ended) IT (Prematurely Ended) HR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003343-29 | Sponsor Protocol Number: ACP-103-064 | Start Date*: 2019-11-15 | |||||||||||
Sponsor Name:ACADIA Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE 2) | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Completed) HU (Completed) BG (Completed) ES (Ongoing) LT (Completed) IT (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
